Suppr超能文献

马萨诸塞州医生对使用抗逆转录病毒药物预防 HIV 态度、知识和经验的演变。

Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention.

机构信息

The Fenway Institute, Fenway Health, Boston, Massachusetts, USA.

出版信息

AIDS Patient Care STDS. 2012 Jul;26(7):395-405. doi: 10.1089/apc.2012.0030. Epub 2012 Jun 13.

Abstract

The Center for the AIDS Programme of Research in South Africa (CAPRISA) 004 and Pre-exposure Prophylaxis Initiative (iPrEx) studies demonstrated that topical or oral chemoprophylaxis could decrease HIV transmission. Yet to have an appreciable public health impact, physicians will need to be educated about these new HIV prevention modalities. Massachusetts physicians were recruited via e-mail to complete an online survey of their knowledge and use of HIV prevention interventions. Data were collected before (July-December, 2010) (n=178) and after (December, 2010-April, 2011) (n=115) the release of iPrEx data. Over the two time intervals, knowledge of oral PrEP significantly increased (79% to 92%, p<0.01), whereas knowledge about topical microbicides was already high (89% pre-iPrEx). Post-iPrEx, specialists were more knowledgeable about oral PrEP (p<0.01) and topical microbicides (p<0.001) than generalists. The majority of the respondents would prefer to prescribe topical microbicides (75%) than oral PrEP (25%; p<0.001), primarily because they perceived fewer side effects (95%). Respondents indicated that PrEP should be available if it were a highly effective, daily pill; however, ongoing concerns included: potential drug resistance (93%), decreased funds for other forms of HIV prevention (88%), medication side effects (83%), and limited data regarding PrEP's clinical efficacy (75%). Participants indicated that formal CDC guidelines would have the greatest impact on their willingness to prescribe PrEP (96%). Among Massachusetts physicians sampled, chemoprophylaxis knowledge was high, but current experience was limited. Although topical gel was preferred, responses suggest a willingness to adapt practices pending additional efficacy data and further guidance from normative bodies. Educational programs aimed at incorporating antiretroviral chemoprophylaxis into physicians' HIV prevention practices are warranted.

摘要

南非艾滋病研究计划和预防暴露前倡议(iPrEx)研究表明,局部或口服化学预防可以降低 HIV 传播。然而,为了产生可观的公共卫生影响,医生需要接受有关这些新的 HIV 预防方法的教育。马萨诸塞州的医生通过电子邮件被招募来完成一项关于他们对 HIV 预防干预措施的知识和使用情况的在线调查。数据是在 iPrEx 数据发布之前(2010 年 7 月至 12 月)(n=178)和之后(2010 年 12 月至 2011 年 4 月)(n=115)收集的。在这两个时间段内,关于口服 PrEP 的知识显著增加(从 79%增加到 92%,p<0.01),而关于局部杀微生物剂的知识已经很高(iPrEx 前为 89%)。在 iPrEx 之后,专家对口服 PrEP(p<0.01)和局部杀微生物剂(p<0.001)的了解比全科医生更多。大多数受访者更愿意开局部杀微生物剂(75%)而不是口服 PrEP(25%;p<0.001),主要是因为他们认为副作用更少(95%)。受访者表示,如果 PrEP 是一种高效的、每日服用的药丸,就应该提供这种药物;然而,目前仍然存在一些担忧,包括:潜在的药物耐药性(93%)、用于其他形式 HIV 预防的资金减少(88%)、药物副作用(83%)以及关于 PrEP 临床疗效的有限数据(75%)。参与者表示,CDC 的正式指南将对他们开 PrEP 的意愿产生最大影响(96%)。在抽样的马萨诸塞州医生中,化学预防知识很高,但目前的经验有限。尽管局部凝胶更受欢迎,但根据进一步的疗效数据和来自规范机构的进一步指导,回应表明愿意调整实践。有必要开展旨在将抗逆转录病毒化学预防纳入医生 HIV 预防实践的教育计划。

相似文献

引用本文的文献

3
Overcoming structural barriers to diffusion of HIV pre-exposure prophylaxis.克服艾滋病毒暴露前预防措施推广的结构性障碍。
J Med Access. 2023 Dec 6;7:27550834231214958. doi: 10.1177/27550834231214958. eCollection 2023 Jan-Dec.

本文引用的文献

3
HIV drug-prevention strategy carries risks.
Nature. 2011 Aug 16;476(7360):260-1. doi: 10.1038/476260a.
4
Estimated HIV incidence in the United States, 2006-2009.2006-2009 年美国估计的艾滋病毒发病率。
PLoS One. 2011;6(8):e17502. doi: 10.1371/journal.pone.0017502. Epub 2011 Aug 3.
5
A US policy perspective on oral preexposure prophylaxis for HIV.美国关于 HIV 口腔暴露前预防的政策视角。
Am J Public Health. 2011 Jun;101(6):982-5. doi: 10.2105/AJPH.2010.300066. Epub 2011 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验